TERF2IP and neoplasm: Validation through multiple Immunohistochemistry (mIHC) confirms the prominence of ARL4C, ARPC1B, and TERF2IP in tumor tissue, and their expression were negatively associated with CD8 T cell presence (Fig. 7E, F).